期刊文献+

CRABP2对肺癌细胞应答全反式视黄酸及细胞增殖的影响 被引量:2

Effect of CRABP2on lung cancer cells in response to all-trans retinoic acid and cell proliferation
原文传递
导出
摘要 目的探讨细胞视黄酸结合蛋白2(CRABP2)对肺癌细胞应答全反式视黄酸(ATRA)及细胞增殖的影响。方法观察两株肺癌细胞95-D和A549对ATRA的敏感性。应用小干扰RNA(siRNA)敲低CRABP2的表达,采用CCK-8和流式细胞术分别检测细胞增殖和周期变化,Western blot检测NF-κB和丝裂原活化蛋白激酶(MAPKs)信号通路分子的表达。结果 ATRA抑制95-D和A549细胞增殖,其中95-D细胞的抑制作用更为明显;而干扰CRABP2的表达则显著降低ATRA对95-D细胞的抑制作用。干扰CRABP2表达在一定程度上能直接抑制95-D细胞增殖,增加G1期的细胞比例,减少S期的细胞,降低NF-κB、应激活化蛋白激酶/c-JUN氨基末端激酶(SAPK/JNK)和c-JUN的磷酸化水平。结论 CRABP2能增强肺癌细胞对ATRA的敏感性,并且还可能通过调控NF-κB和SAPK/JNK信号通路促进细胞增殖,提示CRABP2在肿瘤细胞中的双重作用。 Objective To investigate the effect of cellular retinoic acid binding protein 2(CRABP2)on lung cancer cells in response to all-trans retinoic acid(ATRA)and cell proliferation.Methods The sensitivity of lung cancer cell lines 95-D and A549 to ATRA was observed.After CRABP2 expression was knocked down by siRNA in 95-D cells,the cell proliferation and cell cycle were detected by CCK-8and flow cytometry,respectively.The expressions of NF-κB and mitogenactivated protein kinases(MAPKs)were determined by Western blot.Results ATRA significantly inhibited the proliferation of both lung cancer cells,especially 95-D cells,which were then reversed by CRABP2 siRNA.Moreover,CRABP2 siRNA could directly inhibit the proliferation of 95-D cells,increase the cell proportion in G1 phase,decrease the cell proportion in S phase,and downregulate the phosphorylation levels of NF-κB,SAPK/JNK and c-JUN.Conclusion CRABP2 can enhance the sensitivity of lung cancer cells to ATRA,and may promote cell proliferation via regulating NF-κB and SAPK/JNK signaling pathway suggesting that CRABP2 plays dual roles in cancer cells.
出处 《江苏医药》 CAS 2015年第6期636-639,共4页 Jiangsu Medical Journal
关键词 细胞视黄酸结合蛋白2 肺癌 全反式视黄酸 Cellular retinoic acid binding protein 2 Lung cancer All-trans retinoic acid
  • 相关文献

参考文献11

  • 1申欣,傅士龙,王学敏,李小婷,冯晴.全反式维甲酸对卵巢癌肿瘤DNA拓扑异构酶Ⅱ α 的下调作用[J].江苏医药,2013,39(19):2250-2252. 被引量:1
  • 2刘春梅,黄红铭,秦燕,徐瑞容,尤学芬,滕熔,杨力,徐梦麒,刘红.全反式维甲酸与亚砷酸联合化疗对急性早幼粒细胞白血病高危患者的疗效[J].江苏医药,2012,38(14):1653-1656. 被引量:8
  • 3Wolf G.Cellular retinoic acid-binding proteinⅡ:a coactivator of the transactivation by the retinoic acid receptor complex RAR.RXR[J].Nutr Rev,2000,58(5):151-153.
  • 4Mallikarjuna K,Sundaram CS,Sharma Y,et al.Comparative proteomic analysis of differentially expressed proteins in primary retinoblastoma tumors[J].Proteomics Clin Appl,2010,4(4):449-463.
  • 5Gupta A,Kessler P,Rawwas J,et al.Regulation of CRABP-Ⅱexpression by MycN in Wilms tumor[J].Exp Cell Res,2008,314(20):3663-3668.
  • 6Okuducu AF,Janzen V,Ko Y,et al.Cellular retinoic acidbinding protein 2is down-regulated in prostate cancer[J].Int J Oncol,2005,27(5):1273-1282.
  • 7Goelden U,Pfoertner S,Hansen W,et al.Expression and functional influence of cellular retinoic acid-binding proteinⅡin renal cell carcinoma[J].Urol Int,2005,75(3):269-276.
  • 8Budhu AS,Noy N.Direct channeling of retinoic acid between cellular retinoic acid-binding proteinⅡand retinoic acid receptor sensitizes mammary carcinoma cells to retinoic acidinduced growth arrest[J].Mol Cell Biol,2002,22(8):2632-2641.
  • 9HenklováP,Vrzal R,UlrichováJ,et al.Role of mitogenactivated protein kinases in aryl hydrocarbon receptor signaling[J].Chem Biol Interact,2008,172(2):93-104.
  • 10Cargnello M,Roux PP.Activation and function of the MAPKs and their substrates,the MAPK-activated protein kinases[J].Microbiol Mol Biol Rev,2011,75(1):50-83.

二级参考文献24

  • 1张之南.白血病诊断与疗效标准[M].第2版.北京:科学出版社,1998,171.
  • 2Sanz MA,Lo Coco F,Martin G,et al.Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia:ajoint study of the PETHEMA and GIMEMA cooperative groups[J].Blood,2000,96(4):1247-1253.
  • 3Sanz MA.Treatment of acute promyelocytic leukemia[J].Hematology Am Soc Hematol Educ Program,2006,2006(1):147-155.
  • 4Jing Y,Wang L,Xiu L,et al.Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo[J].Blood,2001,97(1):264-269.
  • 5Sanz MA,Martín G,Gonzlez M,et al.Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy:a multicenter study by the PETHEMA group[J].Blood,2004,103(4):1237-1243.
  • 6Soignet SL,Maslak P,Wang ZG,et al.Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide[J].N Engl J Med,1998,339(19):1341-1348.
  • 7Mathews V,George B,Chendamarai E,et al.Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia:long-term follow-up data[J].J Clin Oncol,2010,28(24):3866-3871.
  • 8Gore SD,Gojo I,Sekeres MA,et al.Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia[J].J Clin Oncol,2010,28(6):1047-1053.
  • 9Powell BL,Moser B,Stock W,et al.Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia:North American Leukemia Intergroup Study C9710[J].Blood,2010,116(19):3751-3757.
  • 10Montesinos P,Díaz-Mediavilla J,Debén G,et al.Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis[J].Haematologica,2009,94(9):1242-1249.

共引文献10

同被引文献7

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部